Related Experiment Video
Updated: Aug 30, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Receptor tyrosine kinases in normal and malignant haematopoiesis
1Royal Hallamshire Hospital, Sheffield, UK. j.t.reilly@sheffield.ac.uk
Abstract:
Haematopoiesis is controlled by a number of growth factors and cytokines, a number of which act through binding to high-affinity receptor tyrosine kinases (RTKs). Approximately 20 different RTK classes have been identified, all of which share a similar structure that includes a ligand binding extracellular domain, a single transmembrane domain and an intracellular tyrosine kinase domain. Recent studies have linked an increasing number of mutations in the RTKs to the pathogenesis of both acute and chronic leukaemia. For example, the FLT3 receptor, a RTK class III, is the most commonly mutated gene in acute myeloid leukaemia, while c-kit mutations are strongly linked to the development of mast cell malignancy. This review summarizes the RTK classes that are known to be expressed on normal haematopoietic tissue and highlights the many 'gain-of-function' mutations involved in leukaemogenesis. It is to be hoped that this knowledge will provide important new insights for targeted therapy in leukaemia.
Related Concept Videos
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Enzyme-linked Receptors
Regulation of Hematopoietic Stem Cells

